Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Hematopoietic cell transplantation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) CCR (1) CDK (1) CXCR (1) DNA/RNA Synthesis (2) Drug Metabolite (2) HIV (1) HOXA (1) HSV (1) Interleukin Related (1) JAK (1) Nucleoside Antimetabolite/Analog (2) SARS-CoV (1)
By Research Areas:	Cancer (4) Infection (2) Inflammation/Immunology (3)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134259

MEISi-2	HOXA	Cancer
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .

HY-P99376

Narsoplimab 1 Publications Verification OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)	SARS-CoV	Infection
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .

HY-108420

INK4C-IN-2 1 Publications Verification	CDK	Cancer
INK4C-IN-2 (Compound 40) is the inhibitor for INK4C (also known as p18) and the activator for CDK4/6. INK4C-IN-2 increases the number and expansion capacity of mouse and human hematopoietic stem cells (HSCs) with EC₅₀ of 5.21 nM, promotes the self-renewal and multilineage differentiation of HSCs. INK4C-IN-2 improves the expansion and long-term hematopoietic reconstruction ability of HSCs in mouse bone marrow transplantation model .

HY-155193

XY-52	Interleukin Related	Inflammation/Immunology
XY-52 (Compound 32) is a Stimulation-2 (ST2) inhibitor, with an IC₅₀ value of 5.68 μM in AlphaLISA assay, and 4.59 μM in HEK-Blue assay. XY-52 increases proinflammatory T-cell proliferation. XY-52 reduces the plasma sST2 and IFNγ biomarkers in the graft versus host disease (GVHD) mice model .

HY-136650A

Fludarabine triphosphate trisodium 1 Publications Verification F-ara-ATP trisodium	Nucleoside Antimetabolite/Analog Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Fludarabine triphosphate (F-ara-ATP) trisodium, the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC₅₀ of 2.3 μM and a K_i of 6.1 μM. Fludarabine triphosphate trisodium inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate trisodium inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis .

HY-120427

Cosalane NSC 658586	CCR CXCR HIV HSV	Infection Inflammation/Immunology
Cosalane (NSC 658586) is a CCR7 (IC₅₀ = 2.43 μM) and CXCR2 antagonist (IC₅₀ = 0.66 μM). Cosalane is an inhibitor of HIV replication with a wide range of activity against HIV-1 isolates, HIV-2, Rauscher murine leukemia virus, HSV-1, HSV-2 and human cytomegalovirus. Cosalane inhibits both attachment of gp120 to CD4. Cosalane inhibits human and murine CCR7 in response to both CCL19 and CCL21 agonists. Cosalane can be studied in research for HIV or attenuating acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) .

HY-161621

JAK-IN-37	JAK	Inflammation/Immunology
JAK-IN-37 (Compound WU4) is a JAK inhibitor, with IC₅₀ values of 0.52, 2.26, 84 and 1.09 nM for JAK1, JAK2, JAK3 and JAK4, respectively. JAK-IN-37 can be used for the research of allogeneic hematopoietic cell transplantation (allo-HCT) .

HY-136650

Fludarabine triphosphate F-ara-ATP	Nucleoside Antimetabolite/Analog Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Fludarabine triphosphate (F-ara-ATP), the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC₅₀ of 2.3 μM and a K_i of 6.1 μM. Fludarabine triphosphate inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis .

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library	3,355 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 3,355 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

3,355 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 3,355 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Cat. No.	Product Name	Target	Research Area

HY-P99376

Narsoplimab 1 Publications Verification OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)	SARS-CoV	Infection
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.